Protagonist Therapeutics Inc PTGX:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 4:00 PM EDT95.41UNCH (UNCH)
Volume
28,846
Close
95.41
+2.18 (+2.34%)
+2.18 (+2.34%)Volume
549,677
52 week range
49.38 - 107.84
- Open93.93
- Day High95.61
- Day Low93.00
- Prev Close93.23
- 52 Week High107.84
- 52 Week High Date04/01/26
- 52 Week Low49.38
- 52 Week Low Date07/08/25
Latest On Protagonist Therapeutics Inc
Key Stats
- Market Cap6.136B
- Shares Out64.31M
- 10 Day Average Volume0.51M
- Dividend-
- Dividend Yield-
- Beta1.83
Latest On Protagonist Therapeutics Inc
KEY STATS
- Open93.93
- Day High95.61
- Day Low93.00
- Prev Close93.23
- 52 Week High107.84
- 52 Week High Date04/01/26
- 52 Week Low49.38
- 52 Week Low Date07/08/25
- Market Cap6.136B
- Shares Out64.31M
- 10 Day Average Volume0.51M
- Dividend-
- Dividend Yield-
- Beta1.83
RATIOS/PROFITABILITY
- EPS (TTM)-1.80
- P/E (TTM)-52.89
- Fwd P/E (NTM)25.77
- EBITDA (TTM)-141.017M
- ROE (TTM)-17.06%
- Revenue (TTM)74.063M
- Gross Margin (TTM)-
- Net Margin (TTM)-154.88%
- Debt To Equity (MRQ)-
EVENTS
- Earnings Date08/04/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREProtagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist...
Harold Selick Ph.D.
Independent Chairman of the Board
Dinesh Patel Ph.D.
President, Chief Executive Officer, Director
Asif Ali
Chief Financial Officer, Executive Vice President
Address
7707 Gateway Blvd Ste 140
Newark, CA
94560-1160
United States